Chimeric Antibody 14D5 Protects Mice against the Far-Eastern, Siberian, and European Tick-borne Encephalitis Virus

Tick-borne encephalitis virus (TBEV), belonging to the Flaviviridae family, is the most significant pathogen transmitted by Ixodes ticks and causing one of the most severe human neuroinfections. In Russia, serum immunoglobulin produced from the donor blood is currently used for post-exposure prophylactic and therapy of tick-borne encephalitis virus. However, it is known that preparations obtained from donated blood have certain disadvantages, and therefore development of novel preparations for post exposure prophylaxis and therapy of tick-borne encephalitis is required. To develop an alternative preparation, which does not include donor blood, a chimeric antibody ch14D5 against glycoprotein E of TBEV was constructed.

This study was aimed to investigate protective efficacy of the chimeric antibody ch14D5 against the Far-Eastern, Siberian, and European subtypes of TBEV in in vivo experiments.

A peripheral mouse model of tick-borne encephalitis was used in this study: the chimeric antibody ch14D5 was administrated intravenously in mice one day after their intraperitoneal infection with TBEV strains Sofjin, Vasilchenko, and Absettarov. Anti-TBEV serum immunoglobulin was used as a control preparation, which was administered in the same way. Protective efficacy of the chimeric antibodies 14D5 was assessed using the log-rank test. In the study, the presence or absence of antibody-dependent enhancement of infection (ADE) was examined when mice, infected with different subtypes of the TBEV, got the antibody ch14d5.

Obtained results demonstrated high efficacy of the ch14D5 antibody in post-exposure prophylaxis of the disease in mice infected with any of the used TBEV strains, as well as the absence of ADE.

It was shown that protective efficacy of antibody ch14D5 is higher than that of the anti-TBEV serum immunoglobulin, and antibody ch14D5 could be used for development of a therapeutic preparation for post-exposure prophylaxis.

1. World Health Organization. Vaccines against tick-borne encephalitis. WHO position paper: recommendations. Vaccine. 2011; 29(48): 8769-8770. doi: 10.1016/j.vaccine.2011.07.024

2. Federal Service on Customers’ Rights Protection and Human Well-Being Surveillance. State report “On the state of sanitary and epidemiological well-being of the Russian Federation population in 2016”. 2017. URL: http://rospotrebnadzor.ru/upload/iblock/0b3/ gosudarstvennyy-doklad-2016.pdf. (In Russ.)

3. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res. 2003; 57(1-2): 129-146. doi: 10.1016/S0166- 3542(02)00206-1

4. Mandl CW. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res. 2005; 111(2): 161-174. doi: 10.1016/j.virusres.2005.04.007

5. Demina TV, Dzhioev YuP, Kozlova IV, Verkhozina MM, Tkachev SE, Doroshchenko EK, et al. Genotypes 4 and 5 of tickborne encephalitis virus: peculiarities of genome structure and possible way of their formation. Voprosy virusologii. 2012; 57(4): 13-18. (In Russ.)

6. Kozlova IV, Demina TV, Tkachev SE, Doroshchenko EK, Lisak OV, Verkhozina MM, et al. Characteristics of Baikal subtype of tick-borne encephalitis virus circulating on the territory of the Eastern Siberia. Acta biomedica scientifica. 2018; 3(4): 53-60. doi: 10.29413/ABS.2018-3.4.9. (In Russ.)

7. Dai X, Shang G, Lu S, Yang J, Xu J. A new subtype of eastern tick-borne encephalitis virus discovered in Qinghai-Tibet Plateu, China. Emerg Microbes Infect. 2018; 7(1): 74. doi: 10.1038/s41426- 018-0081-6

8. Khasnatinov MA, Danchinova GA, Kulakova NV, Tungalag K, Arbatskaya EV, Mironova LV, et al. Genetic characteristics of tickborne encephalitis agent in Mongolia. Voprosy virusologii. 2010; (3): 27-32. (In Russ.)

9. Tsekhanovskaya NA, Matveev LE, Rubin SG, Karavanov AS, Pressman EK. Epitope analysis of tick-borne encephalitis (TBE) complex viruses using monoclonal antibodies to envelope glycoprotein of TBE virus (persulcatus subtype). Virus Res. 1993; 30(1): 1-16.

10. Baykov IK, Matveev AL, Stronin OV, Ryzhikov AB, Matveev LE, Kasakin MF, et al. A protective chimeric antibody to tickborne encephalitis virus. Vaccine. 2014; 32(29): 3589-3594. doi: 10.1016/j.vaccine.2014.05.012

11. Matveev AL, Khlusevich YaA, Baykov IK, Babkin IV, Goncharova EP, Morozova VV, et al. Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus. Vavilovskiy zhurnal genetiki i selektsii. 2017; 21(8): 993-1000. doi: 10.18699/VJ17.324. (In Russ.)

12. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938; 27(3): 493-497. doi: 10.1093/oxfordjournals.aje.a118408

13. Timofeev AV, Kondratieva YuYu, Karganova GG, Stefenson G. Protective activity of bacterial plasmid carrying the tick-borne encephalitis virus non-structural NS1 gene. Voprosy virusologii. 2001; (1): 22-24. (In Russ.)

14. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017; 356(6334): 175-180. doi: 10.1126/science.aal4365

15. Halstead SB. Dengue antibody-dependent enhancement: Knowns and unknowns. In: Crowe J, Boraschi D, Rappuoli R. (eds.) Antibodies for Infectious Diseases. Washington, DC: ASM Press; 2014: 249-271. doi: 10.1128/microbiolspec. AID-0022-2014

16. Halstead SB. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis. 2017; 23(4): 569-573. doi: 10.3201/eid2304.161879

17. Haslwanter D, Blaas D, Heinz FX, Stiasny K. A novel mechanism of antibody-mediated enhancement of flavivirus infection. PLOS Pathogens. 2017; 13(9), e1006643. doi: 10.1371/ journal.ppat.1006643

18. Bröker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about postexposure treatment. Vaccine. 2008; 26(7): 863-868. doi: 10.1016/j. vaccine.2007.11.046

19. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T. Maturation of West Nile virus modulates sensitivity to antibodymediated neutralization. PLoS Pathog. 2008; 4(5): e1000060. doi: 10.1371/journal.ppat.1000060

20. Kreil TR, Eibl MM. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol. 1997; 71(4): 2921-2927.

21. Kozlova IV, Zlobin VI, Verkhozina MM, Demina TV, Dzhioev YuP, Lisak OV, et al. Modern approaches to the emergency specific prophylaxis of tick-borne encephalitis. Voprosy virusologii. 2007; 52(6): 25-30. (In Russ.)